Brote ampollar en un paciente psoriásico
DOI:
https://doi.org/10.51987/Rev.Hosp.Ital.B.Aires.v26i3.1148Resumen
.
Descargas
Referencias
Yancey KB, Egan CA. Pemphigoid: clinical,histologic, immunopathologic, and therapeuticconsiderations. JAMA 2000;284(3):350-6. DOI: https://doi.org/10.1001/jama.284.3.350
Mutasim DF, Bilic M, Hawayek LH, et al.Immunobullous diseases. J Am Acad Dermatol2005;52(6):1029-43. DOI: https://doi.org/10.1016/j.jaad.2004.11.064
McKenna JK, Leiferman KM. Dermatologicdrug reactions. Immunol Allergy Clin North Am2004;24(3):399-423, vi. DOI: https://doi.org/10.1016/j.iac.2004.03.007
Smith EP, Taylor TB, Meyer LJ, et al. Antigenidentification in drug-induced bullouspemphigoid. J Am Acad Dermatol 1993;29(5Pt 2):879-82. DOI: https://doi.org/10.1016/0190-9622(93)70262-R
Lee JJ, Downham TF 2nd. Furosemide-induced bullous pemphigoid: case report andreview of literature. J Drugs Dermatol 2006;5(6):562-4.
Wojnarowska F, Kirtschig G, Highet AS,et al. Guidelines for the management ofbullous pemphigoid. Br J Dermatol 2002;147(2):214-21. DOI: https://doi.org/10.1046/j.1365-2133.2002.04835.x
Joly P, Roujeau JC, Benichou J, et al. Acomparison of oral and topical corticosteroidsin patients with bullous pemphigoid. N Engl JMed 2002;346(5):321-7. DOI: https://doi.org/10.1056/NEJMoa011592
Ahmed AR. Intravenous immunoglobulintherapy for patients with bullous pemphigoidunresponsive to conventionalimmunosuppressive treatment. J Am AcadDermatol 2001;45(6):825-35 DOI: https://doi.org/10.1067/mjd.2001.116337
Leonardi CL. Efalizumab: an overview. J AmAcad Dermatol 200349(2 Suppl):S98-104 DOI: https://doi.org/10.1016/S0190-9622(03)01141-1
Descargas
Compartir artículo
Publicado
Número
Sección
Licencia
Derechos de autor 2006 Revista del Hospital Italiano de Buenos Aires
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
